Detected ·
Windward Bio
$225MOther
Windward Bio, a Basel-based biotech developing ultra-long-acting antibody therapies, went public on Nasdaq at a ~$1B valuation, generating $225M in gross proceeds including a $50M private placement from Sanofi.
- Website
- www.windwardbio.com
- Amount
- $225 000 000 USD
- Stage
- Other
- Event
- Funding round
- Detected
- 2026-11-14 08:02:20 UTC
- Signal ID
- 245d0d59-1b0b-4e83-a40d-befe6dbfd39b
As the API returns it
{
"id": "245d0d59-1b0b-4e83-a40d-befe6dbfd39b",
"created_at": "2026-11-14T08:02:20.773210Z",
"company_name": "Windward Bio",
"company_website_url": "www.windwardbio.com",
"company_linkedin_url": "https://www.linkedin.com/company/windward-bio-001",
"event_type": "funding",
"funding_amount": 225000000,
"funding_currency": "USD",
"funding_stage": "other",
"message": "*Windward Bio, a Basel-based biotech developing ultra-long-acting antibody therapies, went public on Nasdaq at a ~$1B valuation, generating $225M in gross proceeds including a $50M private placement from Sanofi.*"
}